Fibrate therapy in patients with metabolic syndrome and diabetes mellitus

被引：13

作者：

Dayspring T. ^{[1
]}

Pokrywka G. ^{[1
]}

机构：

[1] North Jersey Institute of Menopausal Lipidology, Wayne, NJ 07470

来源：

Current Atherosclerosis Reports | 2006年 / 8卷 / 5期

关键词：

Statin; Ezetimibe; Arterioscler Thromb Vasc Biol; Fibrate Therapy; Diabetes Atherosclerosis Intervention Study;

D O I：

10.1007/s11883-006-0032-x

中图分类号：

学科分类号：

摘要：

Patients with metabolic syndrome and type 2 diabetes mellitus are usually in moderately high-risk, high-risk, or very high-risk cardiovascular categories and present major therapeutic challenges. The dyslipidemia in such patients is typically a disorder of the triglyceride/high-density lipoprotein axis (TG/HDL axis) characterized by an excess of triglyceride-rich lipoproteins and a reduction of HDL. Very often, lifestyle therapy and statin monotherapy fail to achieve guideline goals, necessitating combination therapies. Fibric acids (or fibrates), are agonists of peroxisome proliferator-activated receptor α, which have amassed significant lipid-surrogate and clinical outcome trial data, especially in insulin-resistant patients, typical of those with metabolic syndrome or type 2 diabetes mellitus. Current guidelines advocate fibrate use as an add-on to statin therapy when TG/HDL abnormalities exist in such patients. In this paper, we review pertinent and recent trial data, mechanisms of action, and the safety of fibrate therapy. Copyright © 2006 by Current Science Inc.

引用

页码：356 / 364

页数：8

共 71 条

[1]

Szapary P.O., Rader D.J., The triglyceride-high-density lipoprotein axis: An important target of therapy?, Am Heart J, 148, pp. 211-221, (2004)

[2]

Bjorkegren J., Dual roles of apolipoprotein CI in the formation of atherogenic remnants, Curr Atheroscler Rep, 8, pp. 1-2, (2006)

[3]

Brewer Jr. H.B., Hypertriglyceridemia: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease, Am J Cardiol, 83, (1999)

[4]

Pruneta-Deloche V., Ponsin G., Groisne L., Et al., Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patients, Atherosclerosis, 181, pp. 403-405, (2005)

[5]

Maria Maggi F., Raselli S., Grigore L., Et al., Lipoprotein remnants and endothelial dysfunction in the postprandial phase, J Clin Endocrinol Metab, 89, pp. 2946-2950, (2004)

[6]

Garvey W.T., Kwon S., Zheng D., Et al., Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance, Diabetes, 52, pp. 453-462, (2003)

[7]

Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report, Circulation, 106, pp. 3143-3421, (2002)

[8]

Kahn R., Buse J., Ferrannini E., Et al., The metabolic syndrome: Time for a critical appraisal: Joint statement from the Am Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 28, pp. 2289-2304, (2005)

[9]

Grundy S.M., Cleeman J.I., Daniels S.R., Et al., Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation, 112, pp. 2735-2752, (2005)

[10]

Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study)

← 1 2 3 4 5 6 7 8 →